SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001600620-24-000027
Filing Date
2024-02-29
Accepted
2024-02-29 16:10:10
Documents
14
Period of Report
2024-02-27
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K auph-20240227.htm   iXBRL 8-K 26517
  Complete submission text file 0001600620-24-000027.txt   151409

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT auph-20240227.xsd EX-101.SCH 1932
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT auph-20240227_lab.xml EX-101.LAB 23834
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT auph-20240227_pre.xml EX-101.PRE 12532
15 EXTRACTED XBRL INSTANCE DOCUMENT auph-20240227_htm.xml XML 2719
Mailing Address #140, 14315 - 118 AVENUE EDMONTON A0 T5L 4S6
Business Address #140, 14315 - 118 AVENUE EDMONTON A0 T5L 4S6 250-744-2487
Aurinia Pharmaceuticals Inc. (Filer) CIK: 0001600620 (see all company filings)

IRS No.: 981231763 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36421 | Film No.: 24703683
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)